CREO.L

Creo Medical Group Plc
Creo Medical Group - Award of Shares under Share Incentive Plan
1st August 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 6825Y
Creo Medical Group PLC
01 August 2024
 

 

               

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Award of Shares under Share Incentive Plan, Director Dealings, Issue of Equity and TVR

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020 which is available to all of the Company's UK based employees, including Directors.

 

Under the SIP, shares are acquired in four ways:

 

·    Partnership Shares where an employee can spend up to a £1,800 or 10% of their pre-tax income, whichever is the lower;

·    Matching Shares, where Creo can give up to two free Matching Shares for each Partnership Share bought.  The plan requires employees to remain in employment for three years to benefit from the Matching Shares;

·    Free Shares, where Creo can give up to £3,600 of free shares in any tax year; and

·    Dividend Shares where additional shares can be bought with any dividends paid.

 

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 227,084 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.3275 per Ordinary Share on 16 July 2024 to meet its obligations under the SIP.  Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased (being 454,168 Ordinary Shares in total).  Fiduchi holds 150,740 unallocated shares within the SIP (being shares previously allocated to employees who ceased employment before the shares had vested) which can be utilised to part satisfy the Company's obligation. Accordingly, 303,428 new Ordinary Shares are required to be issued by the Company to be held by Fiduchi as trustee of the SIP.

 

Craig Gulliford, Richard Rees and Christopher Hancock, executive directors of the Company (the "Participating Directors") have received Partnership Shares at a price of £0.3275 per share and Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following this the Participating Directors' shareholdings in the Company are as set out in the table below:

 

Director

Total number of Ordinary Shares purchased or awarded under SIP

Total number of Ordinary Shares held post Transaction

Craig Gulliford, CEO

8,244

1,652,771[1]

Richard Rees, CFO

8,244

2,828,207

Christopher Hancock, CTO

8,244

4,824,657

 

[1] This figure includes 1,000,000 shares held by Mr Gulliford’s wife.


Accordingly, the Company announces that it has made an application for 303,428 new Ordinary Shares to be admitted to trading on AIM.  It is expected that admission will take place on 6 August 2024.  Following the allotment and issue, the Company's issued share capital consists of 361,779,870 Ordinary Shares. The Company does not hold any shares in Treasury. As such the total number of shares in issue with voting rights is 361,779,870.

 

Total Voting Rights (TVR)

 

The above figure of 361,779,870 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.

 

Enquiries:

 

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

Richard Craven (Company Secretary)

+44 (0)1291 606 005



Cavendish Capital Markets Limited

+44 (0)20 7220 0500

Stephen Keys / Camilla Hume (NOMAD)


Michael Johnson (Sales)




Deutsche Numis (Joint Broker)

Freddie Barnfield / Duncan Monteith / Euan Brown

+44 (0)20 7260 1000

 


Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Sam Allen /

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 

 

About Creo Medical

 

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

 

1. Details of PDMR

a)

Name

Craig Gulliford

b)

Position / status

CEO

c)

Initial notification / amendment

Initial notification

2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Purchase of Ordinary Shares under Share Incentive Plan

 

c)

Price(s) and volume(s)

Prices

Volume(s)

£0.3275

2,748

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2024-07-16 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

1. Details of PDMR

a)

Name

Craig Gulliford

b)

Position / status

CEO

c)

Initial notification / amendment

Initial notification

2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Award of Ordinary Shares under Share Incentive Plan

 

c)

Price(s) and volume(s)

Prices

Volume(s)

£0.001

5,496

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2024-07-31 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

1. Details of PDMR

a)

Name

Richard Rees

b)

Position / status

CFO

c)

Initial notification / amendment

Initial notification

2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Purchase of Ordinary Shares under Share Incentive Plan

 

c)

Price(s) and volume(s)

Prices

Volume(s)

£0.3275

2,748

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2024-07-16 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

1. Details of PDMR

a)

Name

Richard Rees

b)

Position / status

CFO

c)

Initial notification / amendment

Initial notification

2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Award of Ordinary Shares under Share Incentive Plan

 

c)

Price(s) and volume(s)

Prices

Volume(s)

£0.001

5,496

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2024-07-31 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

1. Details of PDMR

a)

Name

Christopher Hancock

b)

Position / status

CTO

c)

Initial notification / amendment

Initial notification

2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Purchase of Ordinary Shares under Share Incentive Plan

 

c)

Price(s) and volume(s)

Prices

Volume(s)

£0.3275

2,748

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2024-07-16 GMT

f)

Place of the transaction

London Stock Exchange

 

 

 

1. Details of PDMR

a)

Name

Christopher Hancock

b)

Position / status

CTO

c)

Initial notification / amendment

Initial notification

2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary Shares

b)

Nature of the transaction

Award of Ordinary Shares under Share Incentive Plan

 

c)

Price(s) and volume(s)

Prices

Volume(s)

£0.001

5,496

d)

Aggregated information

 

Aggregated volume Price

N/A - Single transaction

 

e)

Date of the

transaction

2024-07-31 GMT

f)

Place of the transaction

London Stock Exchange

 


[1] This figure includes 1,000,000 shares held by Mr Gulliford's wife.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHRBMMTMTTJTLI]]>
TwitterFacebookLinkedIn